Page last updated: 2024-09-03

gefitinib and jnj38877605

gefitinib has been researched along with jnj38877605 in 3 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(jnj38877605)
Trials
(jnj38877605)
Recent Studies (post-2010) (jnj38877605)
5,2315662,91927125

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)jnj38877605 (IC50)
Nucleoprotein TPRMus musculus (house mouse)0.0086
Hepatocyte growth factor receptorHomo sapiens (human)0.0042
Hepatocyte growth factor receptorMus musculus (house mouse)0.0086

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Damalanka, VC; Janetka, JW; Klampfer, L; Li, S; Mahoney, MW; Primeau, T; Voss, JJLP1

Other Studies

3 other study(ies) available for gefitinib and jnj38877605

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
    Journal of medicinal chemistry, 2021, 12-23, Volume: 64, Issue:24

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Discovery; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Macrocyclic Compounds; Mice; Receptor Protein-Tyrosine Kinases; Serine Proteinase Inhibitors; Structure-Activity Relationship

2021